Experts from all continents discussed the present and future of nephrology and transplantation medicine in emerging countries during a 3-day conference, supported by the World Health Organization, the International Society of Nephrology, the Transplantation Society – Global Alliance for Transplantation and the Ministry of Health of the Republic of Mali. This conference was held in Bamako, Mali on December 4–6, 2008, and focused on prevention and treatment of chronic kidney disease in emerging countries. Apart from delivering high-quality medical and scientific knowledge, the meeting was mainly a call to action for emerging countries to start chronic kidney disease prevention and screening programs, develop end-stage renal disease registries and start or further elaborate transplantation programs. International as well as regional collaborations need to be stimulated and strengthened in order to allow emerging countries to acquire the information, technology, experience and skills necessary to achieve these ambitious goals.

Keywords:
CKD, prevention and transplantation, CKD, emerging countries, Renal disease, screening and prevention, ESRD treatment, emerging countries, Transplantation programs in Africa
1.
The Declaration of Istanbul on Organ Trafficking and Transplant Tourism. Nephrol Dial Transplant 2008;23:3375–3380.
2.
Arogundade FA, Barsoum RS: CKD prevention in Sub-Saharan Africa: a call for governmental, non-governmental, and community support. Am J Kidney Dis 2008;51:515–523.
3.
Bello AK, Nwankwo E, El Nahas AM: Prevention of chronic kidney disease: a global challenge. Kidney Int Suppl 2005;S11–S17.
4.
Mani MK: Experience with a program for prevention of chronic renal failure in India. Kidney Int Suppl 2005;S75–S78.
5.
Hoy WE, Wang Z, Baker PR, Kelly AM: Reduction in natural death and renal failure from a systematic screening and treatment program in an Australian Aboriginal community. Kidney Int Suppl 2003;S66–S73.
6.
Hoy WE, Wang Z, Baker PR, Kelly AM: Secondary prevention of renal and cardiovascular disease: results of a renal and cardiovascular treatment program in an Australian Aboriginal community. J Am Soc Nephrol 2003;14:S178–S185.
7.
Masri MA, Haberal MA, Shaheen FA, et al: Middle East Society for Organ Transplantation (MESOT) Transplant Registry. Exp Clin Transplant 2004;2:217–220.
8.
Rizvi SA, Naqvi SA, Hussain Z, et al: Renal transplantation in developing countries. Kidney Int Suppl 2003;S96–S100.
9.
Najarian JS, Chavers BM, McHugh LE, Matas AJ: 20 years or more of follow-up of living kidney donors. Lancet 1992;340:807–810.
10.
Ibrahim HN, Foley R, Tan L, et al: Long-term consequences of kidney donation. N Engl J Med 2009;360:459–469.
11.
Kasiske BL, Ma JZ, Louis TA, Swan SK: Long-term effects of reduced renal mass in humans. Kidney Int 1995;48:814–819.
12.
Narkun-Burgess DM, Nolan CR, Norman JE, et al: Forty-five year follow-up after uninephrectomy. Kidney Int 1993;43:1110–1115.
13.
Torres VE, Offord KP, Anderson CF, et al: Blood pressure determinants in living-related renal allograft donors and their recipients. Kidney Int 1987;31:1383–1390.
14.
Meier-Kriesche HU, Li S, Gruessner RW, et al: Immunosuppression: evolution in practice and trends, 1994–2004. Am J Transplant 2006;6:1111–1131.
15.
Sheashaa HA, Bakr MA, Fouda MA, et al: Is it worth using daclizumab induction therapy with mycophenolate mofetil-based immunosuppressive regimens in live related donor kidney transplantation? A long-term follow-up. Int Urol Nephrol 2007;39:317–319.
16.
Sheashaa HA, Bakr MA, Ismail AM, et al: Basiliximab induction therapy for live donor kidney transplantation: a long-term follow-up of prospective randomized controlled study. Clin Exp Nephrol 2008;12:376–381.
17.
Sheashaa HA, Hamdy AF, Bakr MA, et al: Long-term evaluation of single bolus high-dose ATG induction therapy for prophylaxis of rejection in live donor kidney transplantation. Int Urol Nephrol 2008;40:515–520.
18.
Webster AC, Playford EG, Higgins G, et al: Interleukin-2 receptor antagonists for kidney transplant recipients. Cochrane Database Syst Rev 2004;CD003897.
19.
Ghisdal L, Touchard G, Goujon JM, et al: First acute rejection episode after renal transplantation: study of the histopathological characteristics according to the immunological risk (in French). Nephrol Ther 2008;4:173–180.
20.
Nashan B: Antibody induction therapy in renal transplant patients receiving calcineurin-inhibitor immunosuppressive regimens: a comparative review. Bio Drugs 2005;19:39–46.
21.
Baquero A, Perez J, Rizik N, et al: Basiliximab: a comparative study between the use of the recommended two doses versus a single dose in living donor kidney transplantation. Transplant Proc 2006;38:909–910.
22.
Remuzzi G, Lesti M, Gotti E, et al: Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trial. Lancet 2004;364:503–512.
23.
Remuzzi G, Cravedi P, Costantini M, et al: Mycophenolate mofetil versus azathioprine for prevention of chronic allograft dysfunction in renal transplantation: the MYSS follow-up randomized, controlled clinical trial. J Am Soc Nephrol 2007;18:1973–1985.
24.
Abramowicz D, Manas D, Lao M, et al: Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen in stable kidney transplant recipients: a randomized, controlled study. Transplantation 2002;74:1725–1734.
25.
Jha V, Muthukumar T, Kohli HS, et al: Impact of cyclosporine withdrawal on living related renal transplants: a single-center experience. Am J Kidney Dis 2001;37:119–124.
26.
Opelz G, Dohler B: Effect on kidney graft survival of reducing or discontinuing maintenance immunosuppression after the first year post-transplant. Transplantation 2008;86:371–376.
27.
Smak Gregoor PJ, de Sevaux RG, Ligtenberg G, et al: Withdrawal of cyclosporine or prednisone six months after kidney transplantation in patients on triple drug therapy: a randomized, prospective, multicenter study. J Am Soc Nephrol 2002;13:1365–1373.
28.
Srinivas TR, Meier-Kriesche HU: Minimizing immunosuppression, an alternative approach to reducing side effects: objectives and interim result. Clin J Am Soc Nephrol 2008;3(suppl 2):S101–S116.
29.
Webster A, Woodroffe RC, Taylor RS, et al: Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients. Cochrane Database Syst Rev 2005;CD003961.
30.
Dominguez J, Kompatzki A, Foradori A, Norambuena R: Ketoconazole alters cyclosporine pharmacokinetic profile and may predispose to acute rejection. Transplant Proc 2003;35:2522–2523.
31.
Ingsathit A, Sumethkul V, Chalermsanyakorn P, Jirasiritham S: Co-administration of diltiazem and cyclosporine for kidney transplant recipients: a four-year follow-up study. J Med Assoc Thai 2006;89(suppl 2):S235–S241.
32.
Smith CL, Hampton EM, Pederson JA, et al: Clinical and medicoeconomic impact of the cyclosporine-diltiazem interaction in renal transplant recipients. Pharmacotherapy 1994;14:471–481.
33.
Carbajal H, Soltero L, Rodriguez-Montalvo C, Valdes A: Cyclosporine and low-dose ketoconazole in renal transplant recipients: a single-center experience. Transplantation 2004;77:1038–1040.
34.
El-Agroudy AE, Sobh MA, Hamdy AF, Ghoneim MA: A prospective, randomized study of co-administration of ketoconazole and cyclosporine a in kidney transplant recipients: ten-year follow-up. Transplantation 2004;77:1371–1376.
35.
Abraham MA, Thomas PP, John GT, et al: Efficacy and safety of low-dose ketoconazole (50 mg) to reduce the cost of cyclosporine in renal allograft recipients. Transplant Proc 2003;35:215–216.
36.
El-Dahshan KF, Bakr MA, Donia AF, et al: Co-administration of ketoconazole to tacrolimus-treated kidney transplant recipients: a prospective randomized study. Nephrol Dial Transplant 2004;19:1613–1617.
37.
Snyder JJ, Israni AK, Peng Y, et al: Rates of first infection following kidney transplant in the United States. Kidney Int 2009;75:317–326.
38.
National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases: US Renal Data System, USRDS 2008 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, NIH, 2008.
39.
Jha V: Post-transplantation infections: an ounce of prevention. Kidney Int 2009 (in press).
40.
Reidenberg MM: Essential medicines for the whole world. Clin Pharmacol Ther 2007;82:500–503.
41.
Fishman JA: Infection in renal transplant recipients. Semin Nephrol 2007;27:445–461.
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.